Tecfidera® (dimethyl fumarate): Updated recommendations in the light of cases of progressive multifocal leukoencephalopathy (PML) in the setting of mild lymphopenia

Dear Healthcare Professional,

In agreement with the European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA), Biogen Netherlands B.V. would like to inform you of important updated information to help minimise the risk of progressive multifocal leukoencephalopathy (PML) in patients treated with Tecfidera.

Summary

- Cases of progressive multifocal leukoencephalopathy (PML) in the setting of mild lymphopenia (lymphocyte count ≥ 0.8 ×10⁹/L and below the lower limit of normal) have been reported in patients treated with Tecfidera; previously, PML had been confirmed only in the setting of moderate to severe lymphopenia.

- Tecfidera is contraindicated in patients with suspected or confirmed PML.

- Tecfidera should not be initiated in patients with severe lymphopenia (lymphocyte counts < 0.5 ×10⁹/L).

- If the lymphocyte count is below the normal range, a thorough assessment of possible causes should be completed before initiating treatment with Tecfidera.

- Tecfidera should be discontinued in patients with severe lymphopenia (lymphocyte counts < 0.5 ×10⁹/L) persisting for more than 6 months.

- If a patient develops PML, Tecfidera must be permanently discontinued.

- Advise patients to inform their partner or caregivers about their treatment and symptoms suggestive of PML, since they may notice symptoms of which the patient is not aware.
**Background on the safety concern**

Tecfidera is authorised in the European Union for the treatment of adults with relapsing-remitting multiple sclerosis. Tecfidera may cause lymphopenia: in clinical trials lymphocyte counts decreased by approximately 30% of baseline values during treatment.

PML is a serious opportunistic infection caused by the John-Cunningham virus (JCV), which may be fatal or result in severe disability. Risk factors for developing PML in the presence of JCV include an altered or weakened immune system.

Among over 475,000 patients exposed to Tecfidera, 11 cases of PML have been confirmed. The single commonality in all 11 confirmed cases is a decreased absolute lymphocyte count (ALC), which is a biologically plausible risk factor for PML. Three of these cases occurred in the setting of mild lymphopenia, while the remaining eight cases developed during moderate to severe lymphopenia.

As currently recommended, all patients should have absolute lymphocyte counts measured before initiating treatment and every 3 months thereafter.

In patients with lymphocyte counts below the lower limit of normal as defined by local laboratory reference range, enhanced vigilance is now recommended and additional factors that may potentially contribute to an increased risk for PML in patients with lymphopenia should be considered. These include:

- duration of Tecfidera therapy. Cases of PML have occurred after approximately 1 to 5 years of treatment, although the exact relationship with duration of treatment is unknown;
- profound decreases in CD4+ and especially in CD8+ T cell counts;
- prior immunosuppressive or immunomodulatory therapy;

In patients with sustained moderate reductions of absolute lymphocyte counts ≥0.5 x 10⁹/L and <0.8 x 10⁹/L for more than six months, the benefit/risk of Tecfidera treatment should be re-assessed.

In addition,

- physicians should evaluate their patients to determine if the symptoms are indicative of neurological dysfunction and, if so, whether these symptoms are typical of MS or possibly suggestive of PML;
- at the first sign or symptom suggestive of PML, Tecfidera should be withheld and appropriate diagnostic evaluations carried out, including determination of JCV DNA in cerebrospinal fluid (CSF) by quantitative polymerase chain reaction (PCR) methodology;
- it is important to note that patients developing PML following recent discontinuation of natalizumab may not present with lymphopenia.

The Tecfidera Product Information is being revised to include the above information.
Call for reporting

Please continue to report suspected adverse drug reactions (ADRs) to the MHRA through the Yellow Card Scheme. Please report:

- all suspected ADRs that are serious or result in harm. Serious reactions are those that are fatal, life-threatening, disabling or incapacitating, those that cause a congenital abnormality or result in hospitalisation, and those that are considered medically significant for any other reason
- all suspected ADRs associated with new drugs and vaccines identified by the black triangle

It is easiest and quickest to report ADRs online via the Yellow Cards website - https://yellowcard.mhra.gov.uk/ or via the Yellow Card app available from the Apple App Store or Google Play Store. Alternatively, prepaid Yellow Cards for reporting are available:

- by writing to FREEPOST YELLOW CARD (no other address details necessary)
- by emailing yellowcard@mhra.gov.uk
- at the back of the British National Formulary (BNF)
- by telephoning the Commission on Human Medicines (CHM) free phone line: 0800-731-6789 or
- by downloading and printing a form from the Yellow Card website (see link above)

When reporting please provide as much information as possible, including information about medical history, any concomitant medication, onset, results of relevant investigations, treatment dates, and product brand name.

Company contact point

Further information can be requested from Biogen by telephone (0800 008 7401), fax (+44 (0) 1628 501 010) or email (MedInfoUKI@biogen.com).

Yours faithfully

Mihaela Vlaicu, MD
Sr. Director, Medical Affairs, UK and Ireland